Understanding details of how arrestins deactivate signaling by G-protein coupled receptors is key to the design of new therapeutics aimed at these cellular “inboxes” that are targeted by up to half of all pharmaceuticals.
Vanderbilt researchers propose that cellular signaling pathways are amplified by a “conveyor belt” mechanism that exchanges active and inactive enzymes.
Vanderbilt researchers are studying how mutations in the receptor for light, rhodopsin, cause light blindness.
Understanding how the main receptor for light interacts with other signaling molecules may inform new pharmaceutical development.
Several Vanderbilt researchers have collaborated with this year’s Nobel Chemistry winners.
Accessibility Tools